Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
Comprehensive clinical development programs being initiated for each investigational candidate
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Subscribe To Our Newsletter & Stay Updated
